chronic rhinosinusitis with nasal polyps
Respiratory · 2021–2025
3decisions
2medicines
3carried consumer input
3individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| omalizumab Initial treatment and continuing treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate response to intranasal… | May 2025 | Recommended with restriction | input received |
| mepolizumab Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients with a blood eosinophil count ≥300 cells/µL (or ≥150 cells/µL if treated with oral… | Nov 2022 | Recommended with restriction | 2 individuals |
| mepolizumab Treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients who have received at least one previous surgery for removal of nasal polyps… | Nov 2021 | Not recommended | 1 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.